Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer

被引：0
|
作者：
de la Calle, Claire Marie
Chang, Albert
Rashid, Ghezal
Wong, Anthony C.
Choi, Alice
Feng, Felix Y.
Gottschalk, Alexander R.
Menzel, Paul Lawrence
Carroll, Peter
Hao Gia Nguyen
机构：
[1] UCSF, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[4] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[5] CPMC, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
323
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial
    Pearse, Maria
    Fraser-Browne, Carol
    Davis, Ian D.
    Duchesne, Gillian M.
    Fisher, Richard
    Frydenberg, Mark
    Haworth, Annette
    Jose, Chakiath
    Joseph, David J.
    Lim, Tee S.
    Matthews, John
    Millar, Jeremy
    Sidhom, Mark
    Spry, Nigel A.
    Tang, Colin I.
    Turner, Sandra
    Williams, Scott G.
    Wiltshire, Kirsty
    Woo, Henry H.
    Kneebone, Andrew
    BJU INTERNATIONAL, 2014, 113 : 7 - 12
  • [42] Controversies in the therapy of high-risk prostate cancer. Radiotherapy
    Boehmer, D.
    ONKOLOGE, 2015, 21 (09): : 805 - +
  • [43] Radiotherapy and hormone therapy in patients with high-risk prostate cancer
    Nature Clinical Practice Urology, 2008, 5 (1): : 4 - 4
  • [44] Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer
    Thoms, John
    Goda, Jayant S.
    Zlotta, Alexendre R.
    Fleshner, Neil E.
    van der Kwast, Theodorus H.
    Supiot, St Phane
    Warde, Padraig
    Bristow, Robert G.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (02) : 107 - 113
  • [45] WHOLE PELVIS RADIOTHERAPY IN PATIENTS WITH HIGH-RISK PROSTATE CANCER
    Spagnoletti, Girolamo
    Marchese, Rita
    Leo, Anna Maria
    Nardella, Grazia
    Piserchia, Maria
    Rignanese, Raffaella
    Bove, Giuseppe
    ANTICANCER RESEARCH, 2012, 32 (05) : 1925 - 1925
  • [46] Radical Radiotherapy for High-Risk Prostate Cancer in Older Men
    Payne, Heather A.
    Hughes, Simon
    ONCOLOGIST, 2012, 17 : 9 - 15
  • [47] Radiotherapy and hormone therapy in patients with high-risk prostate cancer
    Nature Clinical Practice Oncology, 2008, 5 (1): : 8 - 8
  • [48] Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer
    John Thoms
    Jayant S. Goda
    Alexender R. Zlotta
    Neil E. Fleshner
    Theodorus H. van der Kwast
    Stéphane Supiot
    Padraig Warde
    Robert G. Bristow
    Nature Reviews Clinical Oncology, 2011, 8 : 107 - 113
  • [49] Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
    Shore, N. D.
    De Giorgi, U.
    Gleave, M. E.
    Kalac, M.
    Tang, Y.
    Croitoru, R.
    Rosales, M.
    Huynh, M.
    Tammela, T.
    de Jong, I. Jan
    Evans, C.
    Carcano, F. M.
    Freedland, S. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S988 - S989
  • [50] A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design
    Freedland, Stephen J.
    De Giorgi, Ugo
    Gleave, Martin
    Rosbrook, Brad
    Shen, Qi
    Sugg, Jennifer
    Haas, Gabriel P.
    Shore, Neal D.
    BMJ OPEN, 2021, 11 (08):
12345